🔍 Observations
Topline
- Revenue scaled 22.7% YoY to ₹6,812.90 Cr (FY26 vs ₹5,553.96 Cr FY25), marking the strongest annual growth in recent cycles.
- Q4 FY26 revenue of ₹1,811.57 Cr grew 5.3% YoY and 1.9% QoQ — sequential momentum is moderating but holding.
- Full-year growth was broad-based within the single Pharmaceuticals segment; no sub-segment breakout is available.
Bottomline
- PAT nearly tripled YoY: ₹889.85 Cr vs ₹354.41 Cr — a 151% jump driven by operating leverage and a 21% drop in finance costs (₹216 Cr → ₹170.73 Cr).
- Q4 PAT of ₹281.91 Cr grew 20.5% YoY and 11.4% QoQ, confirming consistent quarterly earnings acceleration.
- Effective tax rate held steady at ~24.7% (FY26 292.03 Cr on PBT of 1,181.88 Cr), providing no artificial PAT boost.
Margins
- EBITDA margin expanded 650 bps YoY to 26.9% (FY26: ₹1,832.66 Cr vs FY25: ₹1,130.38 Cr on ₹5,553.96 Cr revenue); Q4 touched 28.9%, the cycle high.
- PAT margin doubled from 6.5% to 13.1% — operating leverage amplified by deleveraging-driven interest savings.
- Employee costs rose faster than revenue (24.5% YoY: ₹895.45 Cr vs ₹719.52 Cr), the one structural margin headwind to monitor.
Growth Trajectory
- The PAT CAGR inflection is steep: ₹354 Cr → ₹890 Cr in one year signals a recovery cycle, not steady-state growth — base effects will moderate future YoY prints.
- Capex stepped up sharply to ₹1,069.95 Cr (FY26) vs ₹641 Cr (FY25), signaling capacity investment for the next growth leg.
- CWIP nearly doubled to ₹773.28 Cr vs ₹458.36 Cr — future depreciation drag is building; revenue from new assets is not yet visible.
🧮 Profit & Loss Statement
🧮 Balance Sheet
🧮 Cash Flows Statement
🟢 Green Flags
- FCF inflection is decisive: OCF of ₹1,623.50 Cr vs ₹601.65 Cr (FY25) — operating cash generation has structurally re-rated, not just recovered.
- Debt deleveraging with growth: Net debt fell to ₹2,284.83 Cr from ₹2,593.54 Cr despite ₹1,070 Cr capex — balance sheet is self-funding expansion.
- Finance cost compression: Interest expense down ₹45.27 Cr YoY (₹216 Cr → ₹170.73 Cr), directly adding to PAT and signaling improving debt mix.
- Margin trajectory is durable: EBITDA margin expanded in every sequential quarter; Q4’s 28.9% is the high watermark and shows no reversion.
- EPS re-rating in one year: Diluted EPS jumped from ₹6.64 to ₹16.45 (+147.7%) — earnings per share nearly tripled on a stable share count, rewarding equity holders.
- Trade payables expansion is working capital positive: Payables rose ₹293.60 Cr (₹958.49 Cr → ₹1,252.09 Cr), extending supplier credit and funding growth without external capital.
🔴 Red Flags
- Inventory build is aggressive: Inventories up ₹405.62 Cr YoY to ₹2,342.16 Cr — outpaces revenue growth of 22.7%, raising demand-visibility risk if offtake slows.
- Trade receivables still elevated: ₹2,155.04 Cr vs ₹2,007.16 Cr; combined with ₹80.77 Cr ECL provisioning, customer credit quality warrants scrutiny.
- ECL provisioning spiked 51%: ₹80.77 Cr vs ₹53.36 Cr (FY25) — indicates deterioration in receivable quality despite rising revenues.
- Other income fell sharply: ₹54.95 Cr vs ₹75.10 Cr (FY25), and Q4 other income was just ₹11.80 Cr vs ₹58.57 Cr in Q4 FY25 — prior-year base included asset sale gains (₹57.05 Cr) that won’t recur.
- Non-current liabilities surged: Up to ₹1,444.40 Cr from ₹1,193.33 Cr, driven by other non-current liabilities jumping ₹191.87 Cr (₹347.60 Cr → ₹539.47 Cr) — nature undisclosed in this filing.
- Employee cost growth outpacing revenue: +24.5% YoY vs revenue growth of 22.7% — margin dilutive if not absorbed by scale.
📊 Balance Sheet Analysis
- Leverage is moderate but improving: Net debt at ₹2,284.83 Cr vs total equity ₹5,431.36 Cr — net D/E of ~0.42x; manageable given OCF of ₹1,623 Cr covering net debt in ~1.4 years.
- Working capital is capital-intensive: Inventory + receivables total ₹4,497.20 Cr (43% of total assets) — pharma-typical but high; any demand slowdown pressures cash.
- Asset base expanding purposefully: Gross fixed assets grew (PPE ₹3,873.23 Cr + CWIP ₹773.28 Cr = ₹4,646.51 Cr) vs ₹4,126.82 Cr prior year — growth capex, not maintenance.
- Equity quality is solid: Total equity grew ₹828.84 Cr YoY (₹4,602.52 Cr → ₹5,431.36 Cr), primarily through retained earnings — no dilutive equity raise.
💰 Cash Flow Analysis
- OCF quality is high: Cash generated from operations of ₹1,917.36 Cr vs PBT of ₹1,181.88 Cr — OCF/PBT of ~1.6x confirms earnings are cash-backed, not accrual-inflated.
- FCF positive despite heavy capex: OCF ₹1,623.50 Cr minus capex ₹1,069.95 Cr = FCF of ₹553.55 Cr — the company is self-funding growth while generating surplus cash.
- Financing outflows disciplined: Net debt repayment (long + short term net) of ₹316.58 Cr plus dividends of ₹86.33 Cr — capital return policy is emerging alongside deleveraging.
- Cash balance remains thin: ₹112.66 Cr on a ₹10,511 Cr asset base — liquidity is managed through working capital lines, not cash reserves; covenant risk exists if credit lines tighten.
💡 Investment Outlook
Laurus Labs has executed a textbook operating leverage cycle in FY26 — revenue up 23%, PAT up 151%, and OCF up 170%, all while reducing net debt despite aggressive capacity investment.
The quality of this recovery is reinforced by FCF generation of ~₹554 Cr and an EBITDA margin touching 28.9% in Q4.
Key watch items heading into FY27 are inventory normalization, the nature of the ₹539 Cr non-current liability build, and whether the CWIP of ₹773 Cr converts to revenue-generating assets on schedule.
For investors, the risk-reward tilts positive if working capital discipline holds and the capex cycle delivers volume — but the high base makes triple-digit PAT growth unrepeatable next year.
Disclaimer: This post features ChartAlert-AI-generated financial content which may contain inaccuracies or errors. This commentary is strictly for informational purposes and does not constitute a recommendation to buy or sell any security. Investors are responsible for performing their own due diligence; always consult with a licensed financial advisor before making investment decisions.
Beyond the Price Action: Fundamental Analysis is Coming to ChartAlert
ChartAlert is evolving into integrated research with a future update that will embed fundamental data into your workflow. Alongside technical analysis, the new release will allow access to financial spreadsheets, quarterly results review, earnings call transcripts, and valuation tools, connecting price action with corporate performance for smarter, data‑driven decisions.